Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 5/20 | 0.55 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CTSH | P09668 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11443315 | 0.90 | CTSC (0.63) | CTSCSLC15A1LTA4HCYP1A2CYP3A4 | |
| SCHEMBL16468683 | 0.84 | CTSC (0.56) | CTSCSLC15A1LTA4HCYP1A2CYP3A4 | |
| SCHEMBL2183798 | 0.84 | CTSC (0.62) | CTSCMMECYP1A2CYP3A4CTSH | |
| SCHEMBL2193162 | 0.83 | CTSC (0.50) | CTSCCYP1A2CYP3A4CTSHCYP2D6 | |
| SCHEMBL2196355 | 0.83 | CTSC (0.43) | CTSCBACE1BACE2OPRD1OPRM1 | |
| SCHEMBL9390903 | 0.82 | CTSC (0.59) | CTSCSLC15A1LTA4HCYP1A2CYP3A4 | |
| SCHEMBL1691349 | 0.81 | CTSC (0.76) | CTSCSLC15A1LTA4HCYP1A2CYP3A4 | |
| SCHEMBL583122 | 0.81 | CTSC (0.76) | CTSCSLC15A1LTA4HCYP1A2CYP3A4 | |
| SCHEMBL9389290 | 0.81 | CTSC (0.76) | CTSCSLC15A1LTA4HCYP1A2CYP3A4 | |
| SCHEMBL583121 | 0.81 | CTSC (0.76) | CTSCSLC15A1LTA4HCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CTSC 331/4885SLC15A1 689/4885LTA4H 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.